Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As US FDA Shutdown Continues, What Will Be The Cost Of Not Spending?

Executive Summary

Bolus of applications could be filed once government reopens, but employee morale and recruitment efforts could suffer drop-off.


Related Content

Global Device Approvals, Weekly Snapshot: FoundationOne CDx In Japan
CDER Recruitment Wins Begin Outnumbering Losses
Is Bloom Gone From Rosy ANDA Approvals Figures?
The Big Spend-Down: US FDA Eyes $159M Reduction In Carryover User Fees
Shutdown Winds Down: Short 'Lapse Period' Likely Means Few Disruptions At US FDA
US Congress Ends Shutdown, Clinches Two-Year Device-Tax Repeal
ANDA Complete Responses Spike In FY 2018, But Why?
FDA Recruitment Hurt By Sequester, Shutdown – Hamburg
Government Shutdown Causes Backlog Of 100 Device Submissions, With More Expected
Shutdown Week Two: Could Sponsors Find A More Focused FDA?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts